Rating Change
HC Wainwright & Co. reiterated its Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on August 20, 2026.
reiterateNASDAQ:RLAY
HC Wainwright & Co. Reiterates Buy Rating on Relay Therapeutics, Inc. (RLAY)
HC Wainwright & Co. reiterated its Buy rating on Relay Therapeutics, Inc.
At publication ·
What changed
Relay Therapeutics, Inc. (NASDAQ:RLAY) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $19.70
- Market capitalization
- $1.4B
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Relay Therapeutics (RLAY) on August 20, 2026, with the stock trading at $19.70 and a market capitalization of $1.4 billion.
Market Context
Relay Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $19.70 with a market capitalization of $1.4B.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Relay Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Relay Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 20, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 14, 2026 | JP Morgan | Overweight | N/A |
| Aug 10, 2026 | Citizens | Market Outperform | N/A |
| Aug 07, 2026 | Barclays | Overweight | N/A |
| Jul 21, 2026 | Goldman Sachs | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View RLAY Stock Page
Frequently Asked Questions
What does the Buy rating mean for RLAY?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Relay Therapeutics, Inc. (NASDAQ:RLAY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RLAY forecast page.